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Foot-and-Mouth Disease (FMD) is an acute viral disease that causes important
economy losses. Vaccines with new low-cost adjuvants that stimulate protective
immune responses are needed and can be assayed in a mouse model to predict
their effectiveness in cattle. Immunostimulant Particle Adjuvant (ISPA), also known as
cage-like particle adjuvant, consisting of lipid boxes of dipalmitoyl-phosphatidylcholine,
cholesterol, sterylamine, alpha-tocopherol, and QuilA saponin, was shown to enhance
protection of a recombinant vaccine against Trypanosoma cruzi in a mouse model. Thus,
in the present work, we studied the effects on themagnitude and type of immunity elicited
in mice and cattle in response to a vaccine based on inactivated FMD virus (iFMDV)
formulated with ISPA. It was demonstrated that iFMDV–ISPA induced protection in mice
against challenge and elicited a specific antibody response in sera, characterized by
a balanced Th1/Th2 profile. In cattle, the antibody titers reached corresponded to an
expected percentage of protection (EPP) higher than 80%. EPP calculates the probability
that livestock would be protected against a 10,000 bovine infectious doses challenge
after vaccination. Moreover, in comparison with the non-adjuvanted iFMDV vaccine,
iFMDV–ISPA elicited an increased specific T-cell response against the virus, including
higher interferon gamma (IFNγ)+/CD8+ lymphocyte production in cattle. In this work, we
report for first time that an inactivated FMDV serotype A vaccine adjuvanted with ISPA is
capable of inducing protection against challenge in a murine model and of improving the
specific immune responses against the virus in cattle.
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INTRODUCTION
Foot-and-Mouth Disease (FMD) is an acute, highly contagious viral vesicle disease, which infects
cloven-hoofed animals including livestock—cattle, pigs, sheep, goats, and buffaloes—as well as wild
species—deer, antelopes, wild pigs, elephants, giraffes, and camelids (1).
The economic losses produced by Foot-and-Mouth Disease Virus (FMDV) infection in bovines
and pigs are due to physical and productive deterioration rather than mortality. Indeed, mortality
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rates are low in adult animals, although they are often high
in young ones due to myocarditis. However, for countries that
export animals and their products, the most relevant economic
impact is connected with restrictions on international trade
(1). Routine vaccination with inactivated FMDV (iFMDV) can
significantly reduce the economic impact of this disease.
FMDV has seven serotypes, known as A, C, O, Asia, SAT 1,
SAT 2, and SAT 3. Different strains are used in different countries
for vaccine formulation. Serotype A/Argentina/2001 (A2001),
isolated in an outbreak of FMD in Argentina in 2000, was used
in the present study as proof of concept (2).
In previous work, we developed an experimental murine
model using FMDV O1 Campos that proved useful to evaluate
the potency of FMDV vaccines. Although mice are not naturally
infected by FMDV, experimental infections can be performed
by intraperitoneal (ip) inoculation. In the murine model, the
humoral and protective responses against FMDV in mice are
correlated with cattle (3–6).
Commercial vaccines contain inactivated virus and adjuvants
to boost the immune response. Adjuvants improve the immune
response elicited against inactivated antigens, direct the immune
response to a particular profile, increase the number of
responding individuals, reduce the amount of vaccine doses,
and/or allow attainment of homogeneous immune responses
(7). It is of great importance to find new adjuvants that
allow reducing the amount of virus in vaccines and that
induce Th1/Th2 responses. Other desirable characteristics
include stability and low cost. Immune stimulating complexes
(ISCOMs) are capable of developing a Th1/Th2 balanced
immune response, in addition to increasing cytotoxic responses
(8–11). ISCOMs are spherical particles of ∼40 nm in diameter,
composed of phospholipids, cholesterol, and saponin, which
can retain the antigen through hydrophobic interactions (8,
12). They have been applied to the development of several
registered vaccines for veterinary applications (10). Recently,
an empty cage-like particle formulation similar to one of
this type of adjuvant, ISCOMATRIX R©, was described. It
was named Immunostimulating Particle Adjuvant (ISPA) and
contains dipalmitoyl-phosphatidylcholine (DPPC), cholesterol
(CHO), stearylamine (STEA), alpha-tocopherol (TOCO), and
Quil A saponin (11, 13). This adjuvant was shown to surpass
conventional adjuvants by improving humoral and cellular
CD4/CD8 responses (11). Notably, it was demonstrated that
vaccination with the transialidase protein of Trypanosoma cruzi
(mTS) formulated with ISPA induced increased humoral and
cellular immune responses that protected mice against challenge
with these parasites (11, 13). Importantly, ISPA preparation can
be easily scaled up.
In this work, we report the effect of ISPA as adjuvant for an
inactivated FMDV vaccine both in a murine model and in cattle.
MATERIALS AND METHODS
Animals
All experiments involving the use of animals were carried out
according to National Agricultural Technology Institute (INTA)
Ethics Manual “Guide for the Use and Care of Experimental
Animals,” under protocol number 24/2016.
Male BALB/c mice, 8–12 weeks old from La Plata University,
Argentina, were used.
Calves seronegative for FMDV by enzyme-linked
immunosorbent assay (ELISA), ∼8–10 months old, were
used in the experiment.
Virus
Binary ethylenimine (BEI)-iFMDV A/Argentina/2001 serotype
(provided by Biogenesis Bago, Buenos Aires, Argentina) was used
in ELISA assays and in the experimental vaccine formulation.
Infectious A/Argentina/2001 serotype, provided by Argentine
National Service of Animal Health (SENASA), was used for
viral challenge. All experiments involving infectious virus were
performed in the BSL-4 OIE (World Organization for Animal
Health) facilities at the Institute of Virology, INTA.
Infective Dose of FMDV for Viral Challenge
To select the infective dose of FMDV, serotype A, groups of 4
mice each were intraperitoneally (ip) inoculated with 500 µL
of 101.5 TCID50/mL, 10
2.5 TCID50/mL, or 10
3.5 TCID50/mL
and monitored for viremia at 24, 48, and 72 h postinfection
(hpi) as described in Quattrocchi et al. (5). Briefly, heparinized
blood withdrawn at different hpi was spread onto BHK-21 cell
monolayers grown in 48-well plates and incubated at 37◦C in
a 5% CO2 atmosphere. Then, cell monolayers were washed
twice with sterile phosphate-buffered saline (PBS). Fresh D-
MEM supplemented with 2% fetal calf serum (FCS) was added
and the cells were incubated for 48 h at 37◦C in 5% CO2. It
was considered that animals were infected if the cell monolayer
presented cytopathic effects after a blind passage. Clinical signs,
including apathy, ruffled fur, respiratory distress, watery eye
discharge, and loss of weight, were daily monitored from 0 to 96
hpi. An infective dose of 102.5 TCID50 was selected out of the
results of these experiments.
Inactivated FMDV Dose to Vaccine
Formulation
To select the iFMDV vaccine dose, dilutions of inactivated
FMDV in PBS containing 1, 0.5, 0.3, or 0.1 µg in a final
volume of 0.2mL were prepared. Groups of mice (n = 8)
were subcutaneously (sc) inoculated with these formulations and
challenged with an ip injection of 102.5 TCID50/mL of infectious
FMDV, A2001 serotype, after 21 days postvaccination (dpv).
Twenty-four hours later, viremia was evaluated as described
earlier. Animals were considered protected if viremia was absent
at this time point, as established in previous studies (4–6,
14–16). Percentages of protection were calculated as 100×
(protected/challenged mice). A dose of 0.3 µg of iFMDV was
selected from the results obtained because induction of 50% of
protection and the adjuvant effect can be detected.
ISPA Production
ISPA adjuvant is composed of alpha-tocopherol (TOCOP),
phosphatidylcholine (DPPC), sterylamine (STEA), cholesterol
(CHOL), and QuilA saponin. The ISPA particles have a cage-
like structure of 73.0 ± 1.5 nm size as assessed by dynamic
light scattering. First, liposomes were prepared with the final
proportions of TOCOP: 0.00074% (0.017mM), DPPC: 0.320%
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(4.35mM), STEA: 0.0216% (0.8mM), and CHOL: 0.143%
(3.70mM). The suspension was then extruded through a 50-nm-
pore membrane and a QuilA saponin solution in acetate buffer
was added to liposomes (6.5 mg/300 µL per mL of liposomes)
and extruded through a 50-nm-pore membrane (11, 13).
Vaccine Formulations and Vaccination
Experiments
The vaccines to be applied in mice were formulated with (1) 0.3
µg of iFMDV in PBS (iFMDV) or (2) 0.3 µg of iFMDV in PBS
mixed with 6 µL of ISPA (iFMDV–ISPA), in a final volume of 0.2
mL/dose. BALB/cmice were immunized with (1) iFMDV (n= 5),
(2) iFMDV–ISPA (n = 5), (3) commercial vaccine (n = 5), (4) 6
µL of ISPA (n= 2), or (5) PBS (n= 2) by the sc route. Mice were
challenged at 21 dpv as described earlier.
The vaccines used in cattle were formulated with (1) 12 µg of
iFMDV in PBS, according to Mattion et al. (2), or (2) the same
formulation with 1mL of ISPA, in a final volume of 2 mL/dose.
Cattle (n = 4, per group) were vaccinated sc at days 0 and
48 as follows: (1) iFMDV, (2) ISPA–iFMDV, or (3) commercial
vaccine. The commercial vaccine consisted of a water-in-
oil single emulsion containing O1/Campos, A24/Cruzeiro,
A/Arg/2000, and A/Arg/2001 iFMDV and was provided
by Biogénesis Bagó.
Measurement of Total IgG and Isotypes
Against FMDV by Sandwich ELISA
Total antibodies (Ab) against FMDV were assessed by ELISA
as described previously (3–5) Briefly, Greiner Microlon R©
plates were coated ON at 4◦C with anti-FMDV rabbit
serum in carbonate–bicarbonate buffer, pH 9.6. After three
washing steps, plates were blocked for 30min at 37◦C
with polyvinylpyrrolidone blocking solution in the case of
mouse sera (0.5M NaCl/0.01M phosphate buffer/0.05% Tween-
20/1mM EDTA/1% polyvinylpyrrolidone 30–40K, pH 7.2) or
with PBS/10% FCS in the case of bovines sera. An optimal
dilution of inactivated FMDV was added in blocking solution.
Plates were incubated at 37◦C for 30min. Then, serially
diluted mouse sera (1:4) or bovine sera (1:5) in blocking
solution were added. After 1 h 20min incubation at room
temperature, plates were washed and an optimal dilution
of horseradish peroxidase (HRP)-conjugated anti-mouse IgG
(H+L) (KPL R©), HRP-conjugated anti-mouse isotypes (Southern
Biotech, Birmingham, AL, USA), HRP-labeled goat anti-bovine
IgG antibody (KPL R©), or HRP-labeled goat anti-bovine IgG1
or IgG2 antibody (KPL R©) was added. Plates were incubated for
1 h at room temperature and then washed. Ortho-phenylene-
diamine (1,2-benzenediamine) dihydrochloride (Sigma Aldrich,
St. Louis, MO, USA) (OPD)/H2O2 was used as the peroxidase
substrate. Reactions were stopped by use of 1.25M H2SO4 and
A492 was measured in an absorbance microplate reader. Positive
and negative control sera were included in every plate. The cut-off
was established as the mean of the values of negative sera (n= 10)
plus two standard deviations.
Measurement of Total FMDV-Specific
Antibodies by Liquid-Phase ELISA
A liquid-phase ELISA test was used according to Hamblin
et al. (17), with modifications (1). Briefly, Greiner Microlon R©
plates were coated overnight at 4◦C with rabbit anti-FMDV
serum diluted to the optimal concentration in carbonate–
bicarbonate buffer, pH 9.6. After washing with 0.05% Tween-
20/phosphate buffered saline (PBST), plates were blocked with
PBST/1% ovalbumin (blocking buffer) for 30min at 37◦C. Mice
or bovine sera were serially diluted (1:10) in blocking buffer in
separate tubes and a fixed amount of inactivated FMDV was
added. After 1 h of incubation at 37◦C with shaking, the virus–
antibody mixtures were transferred to the blocked plates, and
incubated for 1 h at 37◦C. An optimal dilution of guinea pig anti-
FMDV serum in PBS/2% normal bovine serum/2% normal rabbit
serum was added for detection, followed by 1 h of incubation
at 37◦C. Plates were washed and peroxidase-conjugated anti-
guinea pig IgG (Jackson ImmunoResearch, West Grove, PA,
USA) serum diluted in the same buffer was added, followed by
1 h of incubation at 37◦C. OPD/H2O2 was used as peroxidase
substrate as described earlier and A492 was measured in a
microplate reader. Strong positive, weak positive, and negative
bovine reference sera were included in each test for validation.
Antibody titers were expressed as the negative logarithm of the
highest dilution of serum that causes an inhibition of color
development higher than 50% in the average values of the
control samples.
Neutralizing Antibody Titers
Sera samples were examined for anti-FMDV neutralizing
antibodies as described before (16). Briefly, serial dilutions of
complement inactivated sera were incubated for 1 h at 37◦C with
100 TCID50 of infective FMDV. Then virus–serum mixtures
were seeded on BHK-21 monolayers. After 40min at 37◦C,
fresh DMEM/2% FCS was added to the monolayers, which
were incubated at 37◦C, under 5% CO2. Cytopathic effects were
observed after 48 h.
Lymphoproliferation Assay
Murine splenocytes were obtained 21 days after immunization.
Animals were anesthetized and euthanized by cervical dislocation
and spleens were removed.
Cattle Peripheral Blood Mononuclear Cells (PBMCs) were
obtained as described previously (18) by centrifugation of bovine
blood in a Ficoll-PaqueTM plus gradient (GEHealthcare, Chicago,
IL, USA).
Murine splenocytes or PBMCs were labeled with 3µM
carboxyfluorescein diacetate succinimidyl ester (CFSE) in PBS
for 30min at 37◦C. Labeled cells were added to 96-well plates (5×
105 cell/well) in complete RPMI 1640 media supplemented with
10% FCS and 50mM 2-mercaptoethanol and were stimulated
with (1) mock, (2) 2.5µg/mL of iFMDV, or (3) 5µg/mL of
concanavalin A (Sigma Aldrich) as positive control. Cells were
incubated at 37◦C in 5% CO2 atmosphere for 4 days, and
then 0.2% paraformaldehyde was added and cell proliferation
was analyzed by flow cytometry using FACSCalibur R© (Becton
Dickinson, San Jose, CA, USA) and Flowing Software (Turku
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FIGURE 1 | Selection of the infective dose of FMDV, serotype A. Groups of BALB/c mice (n = 4) were ip inoculated with 500 µL of 101.5TCID50, 10
2.5TCID50, or
103.5TCID50/mL of infectious FMDV A/Argentina/2001, and viremia was analyzed at 24, 48, and 72 hpi. (A) Percentage of infected animals at 24, 48, and 72 hpi and
(B) percentage of surviving mice at 24, 48, 72, and 96 h after inoculation with infective FMDV.
Center for Biotechnology, Finland). Results were expressed as
delta proliferation and were calculated as the difference between
the percentage of proliferating cells stimulated with inactivated
virus and the percentage of proliferating cells without stimuli. An
example of flow cytometry gating strategy adopted in this article
is depicted in Supplementary Figure 1.
Surface and Intracytoplasmatic Staining
for IFN-γ-Producing Cells Detection
PBMC were incubated in complete RPMI 1640 media
supplemented with 10% FCS and 50mM 2-mercaptoethanol
and were stimulated with (1) mock, (2) 2.5µg/mL of iFMDV,
or (3) 5µg/mL of concanavalin A (Sigma Aldrich, St. Louis,
MO, USA) as positive control. Cells were incubated for 18 h
in the presence of brefeldin A (BD GolgiPlugTM) (according
to manufacturer recommendations). After washing, cells were
fixed in 0.5% paraformaldehyde and permeated with saponin
(0.1% in PBS). Permeated cells were incubated for 20min at RT
with Alexa Flour 647 anti-bovine interferon gamma (INF-γ;
clone CC302, AbD Serotec, Oxford, UK) or isotype-matched
control antibody. After 20min, cells were washed twice and
stained for 30min at 4◦C with anti-bovine CD4, clone CC8
(AbD Serotec) plus FITC anti-bovine IgG (polyclonal, Jackson
ImmunoResearch); PE anti bovine CD 8 (clone CC63, Bio-Rad)
or FITC anti-bovine WC1 (clone CC15, AbD Serotec). Cells
were then washed and fixed with 0.2% paraformaldehyde. Flow
cytometry was performed in a BD FacsCalibur and analyzed with
Flowing Software (Turku Center for Biotechnology, Finland).
An example of flow cytometry gating strategy adopted in this
article is depicted in Supplementary Figure 2.
Statistical Analysis
The GraphPad InStat R© program (GraphPad, San Diego, USA)
was used. Differences between groups were analyzed by
applying the non-parametric Kruskal–Wallis test, followed by
Mann–Whitney U-test for comparisons between two groups. A
p < 0.05 was considered as an indicator of significant differences.
RESULTS
Selection of the Infective Dose for Viral
Challenge in Mice
A previously developed murine model for FMDV serotype O
vaccine testing was adjusted in this study to serotype A (3–5, 19).
With the aim of selecting the viral challenge dose, unvaccinated
mice were inoculated with different viral infective doses of FMDV
(101.5, 102.5, or 103.5 TCID50 infectious FMDV/mL) and viremia
was assessed at 24, 48, and 72 hpi. Mice were also examined
for clinical signs until 96 hpi. All mice inoculated with 102.5
or 103.5 TCID50 infectious FMDV/mL, but only 80% of those
inoculated with 101.5 TCID50 infectious FMDV/mL, presented
positive viremia at all studied time points (Figure 1A). Survival
was 100% at 24 and 48 hpi with all doses used. At 72 hpi,
one mouse of the group inoculated with 103.5 TCID50/mL died,
and at 96 hpi, one mouse each from the 102.5 TICD50/mL
and the 103.5 TICD50/mL groups died (Figure 1B). As shown
in Table 1, clinical signs started to appear at 24 hpi in mice
inoculated with 102.5 TCID50/mL and 10
3.5 TCID50/mL and
at 48 hpi, all animals in these groups showed signs, including
apathy, ruffled fur, and others. Conversely, no mice infected with
101.5 TCID50/mL showed observable clinical signs at any time
of the experiment.
Taking into account these results, the dose of 102.5 TICD50/mL
infectious FMDV serotype A and the time point of 24 hpi were
chosen to, respectively, perform and assess viral challenge assays.
Selection of the iFMDV Dose for Vaccine
Formulation With ISPA as Adjuvant
To analyze the modulatory effect of ISPA adjuvant on the
immune response, a dose of inactivated FMDV capable of
inducing 50% protection was first selected. To this end, mice were
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TABLE 1 | Clinical signs in mice inoculated with different FMDV A/Argentina/2001 serotype doses.
24 h 48 h 72 h 96 h
101.5 102.5 103.5 101.5 102.5 103.5 101.5 102.5 103.5 101.5 102.5 103.5
Apathy 0/4 0/4 0/4 0/4 4/4 4/4 0/4 4/4 3/3a 0/4 3/3a 2/2b
Ruffled fur 0/4 1/4 3/4 0/4 4/4 4/4 0/4 4/4 3/3a 0/4 3/3a 2/2b
Respiratory distress 0/4 0/4 1/4 0/4 4/4 4/4 0/4 4/4 3/3a 0/4 2/3a 2/2b
Watery eye discharge 0/4 0/4 0/4 0/4 0/4 2/4 0/4 1/4 2/3a 0/4 1/3a 2/2b
Loss of weight 0/4 0/4 0/4 0/4 0/4 0/4 0/4 1/4 1/3a 0/4 2/3a 2/2b
Results are expressed as number of mice with signs/total number of infected mice. Groups of BALB/c mice (n = 4) were ip inoculated with 101.5, 102.5, or 103.5 TCID50/mL of infectious
FMDV, A/Argentina/2001 serotype, and observed for disease indications at 24, 48, 72, and 96 hpi.
aOne animal in this group died.
bTwo animals in this group died.
FIGURE 2 | Selection of iFMDV dose for vaccination of BALB/c mice. Groups of mice (n = 8) were vaccinated with 1, 0.5, 0.3, or 0.1 µg of iFMDV in PBS and
challenged with infective virus after 21 dpv. (A) Percentages of protected animals on viral challenge. Group 0 corresponds to animals inoculated with PBS. Animals
were considered protected if viremia was absent at 24 h post challenge. Protection percentages were calculated as 100× (number of vaccinated animals without
viremia/number of vaccinated animals). (B) Antibodies against FMDV elicited by vaccination with different amounts of iFMDV measured by ELISA at 21 dpv.
vaccinated with 1, 0.5, 0.3, or 0.1 µg of iFMDV in PBS and at
21 dpv challenged with infectious FMDV, serotype A. A dose-
dependent protective effect was observed (Figure 2A), as well as a
concomitant decrease in antibody titers with decreasing amounts
of virus (Figure 2B). Fifty percent of mice vaccinated with 0.3 µg
of iFMDV were protected upon viral challenged, so this dose was
chosen for vaccine formulations.
iFMDV–ISPA Vaccine Confers Total
Protection Against FMDV in Mice With a
Single-Dose Immunization
The protective efficacy of the inclusion of ISPA as adjuvant in
an iFMDV vaccine (iFMDV–ISPA) was tested in mice. Groups of
mice were vaccinated with iFMDV, iFMDV–ISPA, a commercial
vaccine (Biogénesis Bagó), ISPA, or PBS (negative control)
and challenged with infective FMDV at 21 dpv (Figure 3).
Notably, while protection with iFMDV alone was achieved in
40% of mice, inclusion of ISPA in the formulation increased
protection levels to 100% as well as the commercial vaccine.
Animals in mock vaccinated groups inoculated with ISPA or
PBS were not protected, indicating that the viral challenge was
conducted properly.
Murine-Specific FMDV Antibodies and
Neutralizing Antibodies Are Increased
When ISPA Is Used as Adjuvant
Antibody (Ab) responses elicited by iFMDV, iFMDV–ISPA, the
commercial vaccine, ISPA, and PBS were evaluated at 14 and
21 dpv. Total specific FMDV Abs titers were significantly higher
(p < 0.001) as measured by liquid-phase ELISA in the iFMDV–
ISPA group as compared to the iFMDV group (Figure 4A).
Importantly, when the virus neutralization test (VNT) was
applied, neutralizing antibody titers at 21 dpv were significantly
higher in the iFMDV–ISPA group as compared to the iFMDV
group (1.6 ± 0.1 vs. 0.95 ± 0.05, p < 0.001). Neutralizing
Ab titers in the iFMDV–ISPA group were similar to those
in the commercial vaccine group (Table 2). Ab levels in the
iFMDV–ISPA group were similar to those in the commercial
vaccine group.
Analysis of isotype profiles at 21 dpv showed that the iFMDV–
ISPA group achieved higher IgG1 and IgG2a titers (p < 0.05 and
p < 0.001, respectively) than the iFMDV group, and the profile
was similar to that of the commercial vaccine group (Figure 4B).
IgG2b titers were also higher in the iFMDV–ISPA group than in
the iFMDV group (p < 0.001). Finally, there were significantly
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higher IgG3 titers (p < 0.001) in the iFMDV–ISPA group than in
the iFMDV and the commercial vaccine groups.
Immunization With iFMDV–ISPA Induces a
Specific Cellular Immune Response
Against FMDV in Mice
At 21 dpv, FMDV-specific T-cell stimulation levels were
significantly higher in splenocytes derived frommice immunized
with iFMDV–ISPA (p < 0.01) or with commercial vaccine
(p < 0.05) than in those derived from iFMDV, ISPA, or PBS-
inoculated mice (Figure 5).
FIGURE 3 | Protection on viral challenge elicited by different vaccines. Groups
of mice (n = 10) were vaccinated with iFMDV, ISPA-iFMDV, or a commercial
FMD vaccine, and groups of mice (n = 4) were vaccinated with ISPA or PBS
alone, and challenged with infective FMDV at 21 dpv. Protection was
calculated as described for Figure 2. Results are representative of two
independent experiments.
iFMDV–ISPA Vaccine Induces an Increase
of FMDV Abs in Cattle
After promising results obtained in the murine model, the
immune efficacy of the iFMDV–ISPA vaccine was studied in
cattle, a natural host of the virus.
FMDV serologically negative calves (n = 4 per group)
were inoculated (at days 0 and 48) with iFMDV (12 µg) or
iFMDV (12 µg)-ISPA, a commercial vaccine (at day 0) or PBS
(negative control).
At 30 dpv, calves vaccinated with iFMDV–ISPA displayed an
increment in the elicited specific humoral response as compared
to individuals vaccinated with iFMDV alone (p < 0.05), when
measured by liquid-phase ELISA (Figure 6A).
As shown in Figure 6B, at 30 dpv, the iFMDV–ISPA vaccine
induced significantly higher levels of IgG1 isotype antibodies
against FMDV than the iFMDV vaccine (p < 0.05). Moreover,
IgG2 titers also presented significant differences (p < 0.05)
among groups. There were no statistically significant differences
in isotype profiles in the iFMDV–ISPA and the commercial
vaccine group.
VNT results at 30 dpv also showed a significant increase
(p < 0.05) in Ab titers in the iFMDV–ISPA group as compared
to the iFMDV group (Table 3). However, at 48 dpv, decreases
in total and neutralizing Ab titers were observed in the
TABLE 2 | Virus neutralizing antibody titers (VNT) in mice at 21 dpv with different
vaccines.
Vaccine VNT (mean Ab titers ± standard deviation)
iFMDV 0.95 ± 0.05
iFMDV–ISPA 1.7 ± 0.1***
Commercial 1.8 ± 0.1***
ISPA <1.0
PBS <1.0
Titers are expressed as log10 of the reciprocal of the serum dilution that neutralizes 50% of
100 TCID50 of infective FMDV, using the fixed virus–variable serum method. ***Significant
differences with respect to the iFMDV group (p < 0.001).
FIGURE 4 | Antibodies against FMDV elicited by different vaccines in mice. FMDV specific antibody titers were measured by (A) liquid-phase ELISA at 14 and 21 dpv.
Each bar represents the mean (n = 5) Ab titer ± SD in each group. (B) Isotype profile of vaccinated animals at 21 dpv. Data are expressed as the mean Ab titer ± SD.
***p < 0.001; **p < 0.01; *p < 0.05.
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iFMDV–ISPA group. Due to a decreases in VNT, a second
dose was administered to cattle, which resulted in an increase
(p < 0.05) at 76 dpv in the seroneutralizing Abs titers in
the iFMDV–ISPA group as compared to the iFMDV group.
Remarkably, these VNT values were similar to the VNT
induced by the commercial vaccine group. These values are
associated with an 80% Expected Percentage os Protection
FIGURE 5 | Cellular immune response in mice splenocytes at 21 dpv. Animals
were vaccinated with iFMDV, ISPA-iFMDV, ISPA, or PBS. Splenocyte
proliferative response after stimulation with iFMDV was measured by CFSE
loss. Results are expressed as the difference (1%) between the percentage of
proliferating splenocytes stimulated with inactivated virus and the percentage
of proliferating splenocytes without stimuli. **p < 0.01; *p < 0.05.
(20). EPP calculates the probability that livestock would be
protected against a 10 000 bovine infectious doses challenge after
vaccination (1).
Immunization With iFMDV–ISPA Induces a
Specific Cellular Immune Response
Against FMDV in Cattle
When PBMCs from vaccinated calves were stimulated with
iFMDV, a significantly increased lymphoproliferative response
(p < 0.001) was evident in iFMDV–ISPA compared to iFMDV
(Figure 7A). No significant differences were detected between the
iFMDV–ISPA and the commercial vaccine group (p= 0.075).
On the other hand, when lymphocytes stained with anti-
bovine CD4, anti-bovine CD8, and anti-bovine INF-γ and then
studied by flow cytometry, the percentages of IFNγ+/CD8+
lymphocytes from iFMDV–ISPA vaccinated calves were higher
than in animals vaccinated with iFMDV alone (p < 0.05)
(Figure 7B). Concerning CD4+ lymphocytes, a tendency of
an increased production of IFNy was also observed in the
TABLE 3 | Virus neutralizing antibody titers at 30, 48, and 76 days after
inoculating cattle with different vaccines.
VNT (mean of Ab titers ± standard deviation)
Vaccine 30 dpv 48 dpv 76 dpv
iFMDV 1.02 ± 0.02 0.85 ± 0.03 1.4 ± 0.1
iFMDV–ISPA 1.8 ± 0.2* 1.2 ± 0.1* 2.2 ± 0.4*
Commercial 2.1 ± 0.2** 2.0 ± 0.4** 2.6 ± 0.2**
PBS <1.0 <1.0 <1.0
Titers are expressed as log10 of the reciprocal of the serum dilution that neutralizes 50%
of 100 TCID50 infective FMDV, using the fixed virus–variable serum method. Significant
differences against iFMDV group: *p < 0.05; **p < 0.01.
FIGURE 6 | Humoral response elicited in cattle by different vaccines. FMDV-specific antibody titers were measured by liquid-phase ELISA. (A) Each bar represents
the mean Ab titer ± SEM (n = 4) at 15, 30, 48, and 76 dpv. (B) Isotype profiles at 30 dpv, expressed as mean Ab titers ± SD. *p < 0.05.
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FIGURE 7 | Cellular immune response in cattle. (A) Lymphocyte proliferative response after stimulation with iFMDV, A/Arg/2001 serotype, measured by CFSE loss.
Differences (1%) were calculated as (% proliferating PBMCs stimulated with inactivated virus—% proliferating PBMCs without stimuli). (B) Percentages of
CD8+/IFNγ+ or CD4+/IFNγ+ T cells in PBMCs of cattle immunized with iFMDV or iFMDV–ISPA, at 76 dpv. ***p < 0.001; **p < 0.01; *p < 0.05.
iFMDV–ISPA group as compared to the iFMDV group, although
the difference was not statistically significant (p= 0.72).
On the other hand, at 76 dpv, there were no statistically
significant differences in the amounts of γδ T cells or IFN+/γδ T
cells in the iFMDV–ISPA-immunized with respect to the iFMDV-
immunized calves (data not shown).
DISCUSSION
In this work, we used a mouse model to examine the capacity
of an iFMDV formulation containing new cage-like particles
(ISPA), as a new generation adjuvant, to elicit a protective
and specific immune response to FMDV. The results of the
immunological immune response profile obtained in the murine
model were confirmed in calves.
In the murine model, all animals vaccinated with iFMDV–
ISPA were protected against homologous viral challenge while
the protection percentages induced by a non-adjuvanted iFMDV
vaccine were inferior. Individuals vaccinated with ISPA alone
were not protected against viral challenge, showing that the
protective response corresponded to an adaptive response against
the virus and was not due to innate immunemechanisms induced
by the adjuvant.
Total and seroneutralizing Abs against FMDV were
significantly elevated in mice that received iFMDV–ISPA as
compared to the group vaccinated with iFMDV alone. These
results correlate with the protection induced on challenge. It
is noteworthy that neutralizing antibody titers showed a good
correlation with protection levels, substantiating the notion that
they are an in vitro reflection of the immune response that occurs
in vivo (1, 21, 22).
In addition, all isotypes of specific IgG were increased in
iFMDV–ISPA group as compared to the group vaccinated with
iFMDV alone, being IgG2a-b/IgG1 ratio also higher. It has been
reported that murine macrophages could have a virus clarifying
action by complement-fixing isotypes IgG2a, IgG2b, and IgG3
(5, 21, 23). The FcγI receptor (FcγRI), expressed in dendritic cells,
monocytes and macrophages binds to these isotypes (24, 25).
According to Klaus et al. (26) and Kipps et al. (27), IgG2a and
IgG2b are the most effective isotypes in complement activation as
well as in antibody-mediated cellular immune responses. Using
the murine model to evaluate the quality of FMDV vaccines,
Gnazzo et al. (6) reported that vaccine protection is associated
not only with total FMDV antibody levels but also with the
IgG2b/IgG1 ratio and the avidity of sera. Moreover, it has been
reported that mice inoculated with iFMDV plus some adjuvants
generate a complement-fixing IgG profile that correlates with
protection on FMDV challenge (3, 28).
When the specific cellular response to the virus was studied,
an increased lymphoproliferative response was evident in mice
immunized with iFMDV–ISPA. These results suggest that the
ISPA adjuvant improves the adaptive immune response against
FMDV, reaching results similar to those obtained with the
commercial vaccine. Ostrowski et al. (29) and Langellotti et al.
(30) reported that vaccination of mice with inactivated FMDV
induces T-cell responses and has been shown to increase CD8+
numbers in the spleen. Moreover, ISPA-iFMDV formulation
triggers proliferation and IFNγ production in FMDV-specific
CD4+ and CD8+ T lymphocytes (data not shown). It is
well-described that IFN-γ is involved in the isotype switch of
immunoglobulins, leading to an increase in the IgG2a and IgG2b
types (31). This result is in agreement with the high levels of
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IgG2a and IgG2b obtained and the protection levels observed in
the iFMDV–ISPA group. Previous work describes that ISCOMs
improve the dendritic cross-presentation (9, 32–34). These data
indicate that iFMDV adjuvanted with ISPA generates a strong
cellular response, in accord with previous reports of studies that
used cage-like particles.
Similar to what was observed in mice, the iFMDV–ISPA
formulation generated an increase in anti-FMDV antibody titers
in calves as compared to the iFMDV vaccine alone. In addition,
animals immunized with iFMDV–ISPA displayed similar VNT
titers as those immunized with a commercial vaccine approved
by SENASA for vaccination in Argentina. Noteworthy, the
commercial vaccine contains FMDV serotype A24/Cruzeiro,
A/A2001, O1 Campos, and A/Arg2000, all of which bear epitopes
that participate in the immune response against FMDV.
In cattle, numerous studies show a correlation between
antibody titers against FMDV elicited by vaccination and in
vitro and in vivo protection on experimental viral challenge.
These correlations have allowed estimation of the Expected
Percentage Protection to the homologous infection using titers of
systemic α-FMDV Ab measured by liquid-phase ELISA or viral
seroneutralization (19; 21; 1). Total and neutralizing anti-FMDV
Ab titers reached in the iFMDV–ISPA group correspond to an
EPP above 80% (35, 36). Importantly, an acceptable inactivated
vaccine should induce 75% protection in cattle (1). Moreover, in
cattle, IgG1 and IgG2 isotype titers were higher when ISPA was
included as adjuvant in iFMDV vaccines. Bovine macrophages
and neutrophils possess an immunoglobulin receptor to which
IgG2 can bind (37). However, there are reports in which
high IgG1 titers were related to high protection against
FMDV challenge (38, 39). IgG1 is involved in both pathogen
opsonization and seroneutralization in bovines. The particular
role of each bovine IgG isotype in the response against FMDV
has not been deeply characterized yet. In addition, IgG1/IgG2
ratio > 1 is related to FMDV protection and it is used as a
protection parameter when there are low VNTs (39, 40).
Regarding cellular responses, in vitro T-cell stimulation was
significantly higher in cattle PBMCs of the iFMDV–ISPA group
than of the iFMDV group. In addition, IFNγ production
was increased in CD8+ PBMCs derived from iFMDV–ISPA-
immunized cattle. Thus, we here demonstrate that the ISPA-
FMDV vaccine induces a cellular immune response in these
bovines by inducing IFNγ secretion and raising viral-specific
PBMC proliferation. Moreover, IgG1 is usually taken as a
parameter of cellular immune response activation (41, 42).
The role of FMDV cellular immunity responses in a target
species, such as the bovine, is still unclear, although many
reports indicate its relevance to fight the infection. In this way,
specific T-cell-mediated antiviral responses have been observed
in cattle after infection or vaccination (43–45). Also, FMDV
vaccination induces rapid T-cell responses, and FMDV-specific
CD4+ T-cell proliferation has been detected as early as 7 dpv
(46). T-helper cells are necessary for the induction of isotype
switching to generate high-affinity antibodies and to reach a
protective neutralizing response to vaccination with iFMDV (47).
On the other hand, CD8+ T-cell–mediated immune responses
to FMDV have been reported in pigs (45, 48, 49) and cattle
(43, 50, 51). Vaccination with the conventional iFMDV vaccine
induces circulating memory CD8+ T cells which, upon an
appropriate stimulus, can be expanded and are cytotoxic (51).
Stenfeld et al. (52) demonstrated the role of a CTL response in
preventing the FMDV carrier state in vaccinated cattle. Besides,
the percentage of CD4+ lymphocytes and the CD4/CD8 ratio
after vaccination may serve as a parameter to select young sires
with a high immune response against FMDV (53). Moreover,
IFN-γ displays activity against FMDV (54), by controlling viral
replication and spreading within the host through natural killer
cell and macrophage activation (55). Thus, a positive correlation
between IFN-γ response and vaccine-induced protection as
well as reduction of long-term persistence of FMDV has been
observed in cattle (56).
Cattles numbers included in this pilot study was equal to
those used in other preliminary studies on vaccine candidates
(48, 57–59), although it is not enough for statistical analysis (60).
However, the results obtained serve as a proof of concept of the
usefulness of ISPA as adjuvant for FMDV vaccines.
Future work will be devoted to examining whether vaccine
formulations containing ISPA promote the virus presentation
to the immune effectors, and in this way enhance the immune
response generated and the protection obtained. Some authors
have reported that ISCOMs induce local recruitment, activation,
and maturation of immune cells, such as dendritic cells;
granulocytes; F4/80 int cells; and T, B, and NK cells (10, 61, 62),
increasing in this way the chances of the antigen to come into
contact with immune cells. In addition, Brok et al. (34) proved
that saponin-based adjuvants enhance antigen cross-presentation
by dendritic cells and T-cell activation. Moreover, Prochetto et al.
have proved that a vaccine for Trypanosoma cruzi formulated
with ISPA and a recombinant trans-sialidase fraction favorably
modulates the regulatory arm of the immune system to reach
immune protection against the parasite (13).
In conclusion, ISPA displays an important adjuvant activity
for FMDV vaccines, increasing and modulating the humoral and
cellular responses in vaccinated mice and cattle and yielding
enhanced protection against challenge.
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Supplementary Figure 2 | The figure shows representative dot plots, from
bovine PBMCs, used for selecting the lymphocyte region based on side sideward
scatter (SSC) on the y-axis and forward side scatter (FSC) on the x-axis. Then, we
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